In this context, CXCR4 has been reported to be a therapeutic target because TGF-β signaling induces acetylation of the transcription factor KLF5 in PCa with BM, which activates CXCR4, leading to osteoclastogenesis and BM [47, 48]. Here, KLF5 is linked to posterior cortical atrophy.